Tetra Noble have established partnerships with NHS preferred

Enter your details below for more information

cannabis importers and prescribers, with an exclusive portfolio of cannabis genetics.

Investment Opportunity

Tetra Noble forecasts combined revenues of €133m in year 4 of operations

12.5% fixed returns per annum for 4 years

Plus, an opportunity to buy shares at 50% discount

The project operating in Portugal

Disclaimer: Any person accessing the email and considering potential investment opportunities featured on the email should make their own commercial assessment after seeking the advice of an appropriately authorised or regulated financial advisor. This opportunity is only suitable for high net worth or self-sophisticated investors as defined here. This email should not be construed as advice or a personal recommendation to any prospective investor. Investments of this nature carry risks to your capital and can go up or down. Past performance is not indicative of future results. Suitable only for sophisticated or high net worth investors.